TrialJournal of cardiovascular pharmacology2017

Efficacy and Safety of Vernakalant for Cardioversion of Recent-onset Atrial Fibrillation in the Asia-Pacific Region: A Phase 3 Randomized Controlled Trial.

Gregory N Beatch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.